Tacrolimus-Induced Elevation in Plasma Triglyceride Concentrations After Administration to Renal Transplant Patients Is Partially Due to a Decrease in Lipoprotein Lipase Activity and Plasma Concentrations
Authors:
- Kristina Sachs-BarrableKSKristina Sachs-Barrable
- Caylee-Britt GoshkoCGCaylee-Britt Goshko
- John S. HillJHJohn S. Hill
- Kishor M. WasanKWKishor M. Wasan
- 15 July 2009
- journal article
- clinical trial
- Published by Wolters Kluwer Health in Transplantation
- Vol. 88 (1) , 62-68
Abstract
Hyperlipidemia is a frequent and persistent complication in solid organ transplant recipients, leading to the high occurrence of cardiovascular disease in this patient population. Lipid abnormalities including increased total cholesterol, triglycerides (TG), and low-density lipoprotein-cholesterol have been reported frequently in transplantation patients and a variety of immunosuppressive therapies seem to be one of the main factors that influence posttransplant lipidemic profiles. For many years, tacrolimus (TAC) has been used as an immunosuppressive drug in transplantation. The aim of our investigation was to determine the effect of TAC administration on the plasma lipid profile and some key regulatory proteins of plasma lipid metabolism including cholesterol ester transfer protein, hepatic lipase and lipoprotein lipase (LPL) within renal transplant patients. Twenty-five renal transplant patients were recruited and received TAC therapy, of which nine of these patients were treated with statin therapy for dyslipidemia. The effects of TAC on plasma total cholesterol, TG, HDL-C, low-density lipoprotein-cholesterol, cholesterol ester transfer protein, hepatic lipase and LPL concentration and activity were determined from patients plasma samples collected before the transplant surgery (baseline), and weekly for four consecutive weeks after surgery and TAC administration. We observed that TAC significantly increases plasma TG concentrations and reduces LPL plasma concentration and activity in renal transplant patients, independent of any lipid lowering drug treatment patients received. Taken together, these findings suggest that the reduction in LPL activity, partly due to the decrease of plasma LPL concentration after TAC administration may be an explanation for hypertriglyceridemia observed in patients administered TAC.Keywords
This publication has 32 references indexed in Scilit:
- Correlation between lipid abnormalities and immunosuppressive therapy in renal transplant recipients with stable renal functionInternational Urology and Nephrology, 2007
- Cardiovascular Complications After Renal Transplantation and Their PreventionTransplantation, 2006
- Long‐term Cardiac Outcomes in Renal Transplant Recipients Receiving Fluvastatin: The ALERT Extension StudyAmerican Journal of Transplantation, 2005
- Conversion From Cyclosporine Microemulsion to Tacrolimus-Based Immunoprophylaxis Improves Cholesterol Profile in Heart Transplant Recipients With Treated but Persistent Dyslipidemia: The Canadian Multicentre Randomized Trial of Tacrolimus vs Cyclosporine MicroemulsionThe Journal of Heart and Lung Transplantation, 2005
- Risk Factors for Reaching Renal Endpoints in the Assessment of Lescol in Renal Transplantation (ALERT) TrialTransplantation, 2005
- TacrolimusDrugs, 2003
- HYPERLIPIDEMIA AND CARDIOVASCULAR DISEASE AFTER ORGAN TRANSPLANTATIONTransplantation, 2001
- Mycophenolate Mofetil Treatment Reduces Atherosclerosis in the Cholesterol-Fed RabbitJournal of Surgical Research, 2000
- Tacrolimus-based triple-drug immunosuppression minimizes serum lipid elevations in pediatric cardiac transplant recipients1999
- Long-term survivors of pediatric heart transplantation: A multicenter report of sixty-eight children who have survived longer than five yearsThe Journal of Pediatrics, 1997